Nicholas Saraceno, Senior Editor

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

The collaboration is powered by the discovery and development of obesity, type 2 diabetes, and cardiovascular disease treatments.

The new form of the vaccine would remove the need for HCPs to combine the powder antigen and liquid adjuvant themselves prior to administering.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, describes the progression of the sample distribution process.

The program intends to address supply chain challenges surrounding product safety, traceability, and counterfeiting.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), describes the randomized clinical trial involving psilocybin that he participated in.

What is the value in US adults addressing these risks, and how do social determinants of health play a role?

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), addresses the importance of stopping the spread of misinformation when it comes to psychedelics.

The deal is expected to be finalized by the first half of this year.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), explains why this resource is an asset, specifically for research in the psychedelic space.

The move—one that meet’s industry standards—confirms the Cryoport company’s commitment to providing quality and safety in the cold chain solutions space.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jon Kostas, executive director, Association for Prescription Psychedelics (APP), provides a peek into what the association has set out to accomplish.

In the final part of this roundtable discussion, a panel of subject matter experts discuss what the future holds for this technology, why end-to-end visibility is necessary in healthcare, and the opportunities for greater RFID adoption that lie ahead.

Is this level of involvement with HRSNs associated with higher burnout?

This bucket of Pharma Commerce coverage is highly powered by digital solutions.

Pharma Commerce was on the road extensively throughout 2024, and plenty of insight was gathered along the way.

A dive into the top articles in this sector making waves this year.

The latest in container tech and temperature-monitoring truly powered the content.

The Drug Supply Chain Security Act was a major coverage area for Pharma Commerce in 2024.

In the fifth part of this roundtable discussion, subject matter experts discuss the role that various GS1 initiatives have played, and provide a breakdown of stakeholders who have benefitted greatly from RFID.

As a result, the provider increases its involvement in the country’s pharma sector.

A cohort study explores the connection between the two, along with the impact of educational attainment on this relationship.

Vibhu Tewary offers insight on this market segment, including a behind-the-scenes of what goes into designing a report.

The 430,000 square-foot finished production facility will house multiple product types within the rare disease sector, including hemophilia.

A panel examines the gross-to-net bubble across various product mixes, how pricing impacts market access, and more.

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success.

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.

A session investigates the drivers of these shortages and ways to mitigate them.

The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.